Oxcarbazepine Suspension
Product Images NDC 72888-074

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 72888-074). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxcarbazepine 300 mg/5 mL Oral Suspension (NDC 72888-074-14)

Label for Oxcarbazepine Oral Suspension USP 300 mg/5mL, an oral prescription medication by Advagen Pharma Ltd. The carton indicates a 250 mL bottle, NDC 72888-074-14, with instructions to dispense a Medication Guide to each patient. Storage instructions and usage notes are also visible, along with the Advagen logo and distributor information.*

FDA Label Image

Oxcarbazepine Chemical Structural. (Oxcarbazepine Oral Susp Chemical Structural)

Chemical structure of Oxcarbazepine, showing its bicyclic ring system with a ketone and amide group attached.*

FDA Label Image

Oxcarbazepine 300 mg/5 mL Oral Suspension (NDC 72888-074-14)

Label for Oxcarbazepine Oral Suspension, USP 300 mg/5 mL, 250 mL bottle. The label includes dosing and storage instructions, a barcode, and states the product is distributed by Advagen Pharma Limited, Plainsboro, NJ, USA. It advises shaking well before use and using within 7 weeks of opening.*

FDA Label Image

Oxcarbazepine Oral Susp Figure 1. (Oxcarbazepine Oral Susp Fig 1)

A Kaplan-Meier survival curve showing the exit rate over time from Day 2 to Day 11 for two groups: one treated with oxcarbazepine and the other with placebo. The graph includes a log-rank test p-value of 0.0001, indicating a statistically significant difference between the treatment groups.*

FDA Label Image

Oxcarbazepine Oral Susp Fig-1a (Oxcarbazepine Oral Susp Fig 1a)

OXCARBAZEPINE 300 mg/5 mL oral suspension illustrated as a vial or bottle cap closure, likely a child-resistant cap, seen from above and side. This image shows the container's screw cap design, but no container or labeling is visible. Labeler is Advagen Pharma Ltd.*

FDA Label Image

Oxcarbazepine Oral Susp Fig-1b (Oxcarbazepine Oral Susp Fig 1b)

An instructional illustration showing a hand holding and shaking an oral suspension bottle, with motion lines indicating the bottle is being shaken to mix the contents.*

FDA Label Image

Oxcarbazepine Oral Susp Fig-1c (Oxcarbazepine Oral Susp Fig 1c)

An instructional illustration showing a hand shaking an oral suspension bottle to mix the medication. The image emphasizes proper suspension preparation before use.*

FDA Label Image

Oxcarbazepine Oral Susp Figure 2. (Oxcarbazepine Oral Susp Fig 2)

A Kaplan-Meier survival curve chart showing seizure rate over time in days from first dose to first seizure. Two treatment groups are compared: Oxcarbazepine (solid line) and Placebo (dashed line). The chart includes statistical information with a log-rank test p-value of 0.046.*

FDA Label Image

Oxcarbazepine Oral Susp Fig-2a (Oxcarbazepine Oral Susp Fig 2a)

The image shows a bottle-style container, presumably for oral suspension medication. It has a white screw cap and a tapered neck, wide at the base. No visible label or text is present on the bottle. The product inside appears as a homogenous liquid.*

FDA Label Image

Oxcarbazepine Oral Susp Fig-2b (Oxcarbazepine Oral Susp Fig 2b)

An instructional illustration showing hands opening a bottle by unscrewing the cap, indicated by a downward arrow. The bottle is presumably for an oral suspension medication, with the cap placed to the side.*

FDA Label Image

Oxcarbazepine Oral Susp Fig-2c (Oxcarbazepine Oral Susp Fig 2c)

An instructional illustration showing a hand using a syringe to withdraw medication from a bottle, with a downward arrow indicating the syringe is being inserted into the bottle's opening. This likely relates to measuring or administering OXCARBAZEPINE oral suspension 300 mg/5 mL.*

FDA Label Image

Oxcarbazepine Oral Susp Figure 3. (Oxcarbazepine Oral Susp Fig 3)

A Kaplan-Meier survival curve showing time to exit (days) for two treatment groups labeled HIGH and LOW. The vertical axis represents exit rate from 0 to 1.0 and the horizontal axis shows time in days up to 130, with the HIGH group depicted by a solid line and LOW group by a dotted line. A log-rank test p-value of 0.0001 is indicated.*

FDA Label Image

Oxcarbazepine Oral Susp Fig-3a (Oxcarbazepine Oral Susp Fig 3a)

Illustration of a syringe showing labeled parts: the barrel and the plunger. The syringe is depicted as a clear graduated cylinder used for measuring liquid volumes.*

FDA Label Image

Oxcarbazepine Oral Susp Fig-3c (Oxcarbazepine Oral Susp Fig 3c)

An instructional illustration showing a hand holding an oral syringe attached to a bottle, with an up and down arrow indicating the action of drawing liquid suspension from the bottle into the syringe.*

FDA Label Image

Oxcarbazepine Oral Susp Figure 4. (Oxcarbazepine Oral Susp Fig 4)

A Kaplan-Meier survival curve graph comparing time to exit (days) between two treatment groups, labeled HIGH and LOW. The vertical axis indicates exit rate from 0 to 1, and the horizontal axis represents time in days up to 130. The log-rank test p-value is 0.0001, suggesting statistical significance.*

FDA Label Image

Oxcarbazepine Oral Susp Fig-4c (Oxcarbazepine Oral Susp Fig 4c)

An instructional illustration showing how to measure a dose of oxcarbazepine oral suspension 300 mg/5 mL using a dosing syringe. The image highlights the syringe filled to the 8 mL mark, demonstrating the correct dose measurement technique with an arrow indicating downward pressure on the plunger.*

FDA Label Image

Oxcarbazepine Oral Susp Fig-5c (Oxcarbazepine Oral Susp Fig 5c)

An instructional illustration showing a hand drawing oral suspension medication from a bottle using a syringe. The image demonstrates turning the syringe to measure the dose accurately, relevant to oral suspension dosage forms like Oxcarbazepine 300 mg/5 mL.*

FDA Label Image

Oxcarbazepine Oral Susp Fig-6c (Oxcarbazepine Oral Susp Fig 6c)

An instructional illustration showing administration of oral suspension using an oral dosing syringe. One part depicts a person receiving the medication from the syringe placed in the mouth, while the other part shows the syringe being filled from a cup containing the suspension.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.